Table 3.
Univariate and multivariate analyses of the prognostic factors of hepatocellular carcinoma patients receiving transcatheter arterial infusion chemotherapy
| Variable |
Univariate analysis |
Multivariate analysis |
||
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Sex (male) | 1.20 (0.60-2.37) | 0.62 | ||
| Age (≥ 70 yr) | 0.94 (0.59-1.70) | 0.81 | ||
| ECOG-PS (1 or 2) | 2.81 (1.58-5.02) | < 0.01 | 2.38 (1.29-4.39) | < 0.01 |
| Platelet count (≥ 10.0 × 104/mm3) | 2.07 (1.22-3.53) | < 0.01 | ||
| AST (≥ 70 IU/L) | 1.55 (0.92-2.61) | 0.10 | ||
| ALT (≥ 53 IU/L) | 1.23 (0.73-2.09) | 0.44 | ||
| LDH (≥ 230 IU/L) | 1.92 (1.14-3.22) | 0.01 | 2.03 (1.19-3.45) | < 0.01 |
| Total bilirubin (≥ 1.0 mg/dL) | 1.88 (1.11-3.18) | 0.02 | ||
| Albumin (≥ 3.0 g/dL) | 0.80 (0.43-1.48) | 0.47 | ||
| Prothrombin (≥ 70%) | 0.48 (0.26-0.88) | 0.02 | ||
| Maximum tumor diameter (≥ 30 mm) | 1.27 (0.74-2.16) | 0.39 | ||
| Tumor distribution (bilateral) | 1.12 (0.62-2.02) | 0.71 | ||
| Portal vein tumor thrombosis | 1.78 (0.45-2.19) | 0.14 | ||
| AFP (≥ 100 mg/ml) | 1.25 (0.74-2.11) | 0.40 | ||
| DCP (≥ 1000 mAU/mL) | 1.20 (0.67-1.45) | 0.33 | ||
| Prior TACE | 2.38 (1.34-4.24) | < 0.01 | 2.34 (1.28-4.28) | < 0.01 |
HR: Hazard ratio; CI: Confidence interval; ECOG-PS: Eastern Cooperative Oncology Group-performance status; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; LDH: Lactate dehydrogenase; AFP: alpha-fetoprotein; DCP: Des-γ-carboxy prothrombin; TACE: Transcatheter arterial chemoembolization.